Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

PHASE3CompletedINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

January 31, 2011

Conditions
Recurrent Glioblastoma Multiforme
Interventions
DEVICE

NovoTTF-100A

multiple four-week courses of continuous NovoTTF-100A treatment

Trial Locations (25)

10021

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medical College, New York

10032

Columbia University Medical Center, New York

15232

University of Pittsburgh Medical Center (UPMC), Pittsburgh

24105

University Hospital of Schleswig-Holstein, Kiel

44106

University Hospitals of Cleveland, Cleveland

53226

Medical College of Wisconsin, Milwaukee

60201

Evanston Northwestern Healthcare, Evanston

60611

Northwestern University, Chicago

60612

University of Illinois in Chicago, Chicago

64239

Tel Aviv Sourasky Medical Center, Tel Aviv

02118

Boston University Medical Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01850

Lahey Clinic Medical Center, Burlington

08818

NJ Neuroscience Institute - JFK Medical Center, Edison

Unknown

Cleveland Clinic, Cleveland

University of Virginia, Charlottesville

University Hospital Graz, Graz

FN Brno - Masaryk University, Brno

Na Homolce Hospital, Prague

Hospital of Neurology Lyon - University Claude Bernard Lyon 1, Lyon

Group Hospitals Pitie-Salpetriere, Paris

University Hospital Augsburg, Augsburg

University Medical Center Hamburg-Eppendorf, Hamburg

Centre Hospitalier Universitaire Vaudois, Lausanne

All Listed Sponsors
lead

NovoCure Ltd.

INDUSTRY

NCT00379470 - Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | Biotech Hunter | Biotech Hunter